PQQ Crystal Form B Low Hygroscopicity Preparation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current research lacks a stable and non-hygroscopic crystal form of pyrroloquinoline quinone (PQQ) with regular morphology, which is crucial for drug development due to its polymorphism and varying properties affecting drug safety and efficacy.
Innovation Solution
A new crystal form B of pyrroloquinoline quinone is developed using specific nucleation methods and conditions, characterized by distinct diffraction peaks, low hygroscopicity, and a decomposition temperature of 260 °C, achieved through vacuum drying of PQQ acid at controlled temperatures, resulting in high crystallinity and regular morphology.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If conventional crystallization methods are used for PQQ, then various crystal forms can be obtained, but the crystal forms exhibit high hygroscopicity and irregular morphology
Solution Approach 1:
The invention changes the crystallization parameters by using specific solvents (acetone, ethanol, isopropanol, n-butanol, or their mixtures with water) and controlled temperature conditions during the crystallization process. This parameter optimization leads to Crystal Form B with improved stability and reduced hygroscopicity compared to conventional crystallization methods
Solution Approach 2:
The invention utilizes the phase transition of PQQ from amorphous or irregular crystal states to a well-defined crystalline state (Crystal Form B) through controlled crystallization. This phase transition results in a stable crystal structure with low hygroscopicity and regular morphology, suitable for pharmaceutical applications
2Adaptability or versatility
If various crystallization conditions are explored, then different polymorphs can be discovered, but the preparation process becomes complex and time-consuming
Solution Approach 1:
The invention identifies and optimizes key crystallization parameters (solvent type, temperature, pH) to directly obtain Crystal Form B with desirable properties. This targeted parameter optimization avoids the need to screen numerous crystallization conditions, simplifying the preparation process while ensuring reproducible results
Solution Approach 2:
The invention performs preliminary optimization of crystallization conditions to establish a standardized preparation method for Crystal Form B. By pre-determining the optimal solvent system and crystallization parameters, the process becomes straightforward and reproducible, eliminating the need for complex iterative exploration
3Reliability
If PQQ is used in pharmaceutical formulations, then therapeutic effects can be achieved, but varying crystal forms affect drug safety and efficacy
Solution Approach 1:
The invention optimizes crystallization parameters to produce Crystal Form B with consistent and reproducible physicochemical properties. This standardized crystal form ensures uniform drug performance, stability, and bioavailability, addressing the variability issues associated with different PQQ polymorphs in pharmaceutical applications
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystal form B exhibits high crystallinity, low hygroscopicity, and improved physicochemical properties, enhancing drug processing and stability, with a simple and reproducible preparation method.
Implementation Method 1
A new crystal form B of pyrroloquinoline quinone is developed using specific nucleation methods and conditions, characterized by distinct diffraction peaks, low hygroscopicity, and a decomposition temperature of 260 °C, achieved through vacuum drying of PQQ acid at controlled temperatures
Implementation Method 2
A new crystal form B of pyrroloquinoline quinone is developed using specific nucleation methods and crystallizing conditions, resulting in high crystallinity and regular morphology
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
The present invention relates to the technical field of chemical drugs and crystal form processes, and to a pyrroloquinolin quinine B crystal form and a preparation method therefor. The present invention comprehensively characterizes the pyrroloquinoline quinine B crystal form by virtue of means such as X-ray powder diffraction analysis, thermo-gravimetric analysis, and differential scanning calorimetry analysis so as to find the fact that the pyrroloquinoline quinine B crystal form is high in crystallinity and low in hygroscopicity, and a regular crystal form can be formed, thereby facilitating process treatment and improvement of physical and chemical properties of a medicine, and improving the patent medicine performance. The preparation method for the pyrroloquinoline quinone B crystal form provided in the present invention is simple, easy to control, and high in reproducibility.